Canaccord Genuity Starts Aduro Biotech (ADRO) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
BofA/Merrill Lynch Starts Aduro Biotech (ADRO) at Buy
May 11, 2015 7:23 AM EDTBofA/Merrill Lynch initiated coverage on Aduro Biotech (NASDAQ: ADRO) with a Buy rating.
For an analyst ratings summary and ratings history on Aduro Biotech click here. For more ratings news on Aduro Biotech click here.
Shares of Aduro Biotech closed at $30.85 yesterday.
... MoreWilliam Blair Starts Aduro Biotech (ADRO) at Outperform
May 11, 2015 7:20 AM EDTWilliam Blair initiated coverage on Aduro Biotech (NASDAQ: ADRO) with an Outperform rating.
For an analyst ratings summary and ratings history on Aduro Biotech click here. For more ratings news on Aduro Biotech click here.
Shares of Aduro Biotech closed at $30.85 yesterday.
... MoreLeerink Partners Starts Aduro Biotech (ADRO) at Outperform
May 11, 2015 6:29 AM EDTLeerink Partners initiates coverage on Aduro Biotech (NASDAQ: ADRO) with a Outperform rating and a price target of $48.00.
Analyst Howard Liang commented, "We are initiating coverage of Aduro BioTech (ADRO) with an Outperform rating and price target of $48/share. ADRO is a clinical-stage... More
